He Zexi, Gong Chen, Gu Jun, Wang Wei, Li Haihao, Tan Zhiyong, Wang Haifeng, Wang Jiansong, Ding Mingxia, Huang Yinglong
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Urological Disease Clinical Medical Center of Yunnan Province, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Eur J Med Res. 2025 Aug 13;30(1):740. doi: 10.1186/s40001-025-03033-0.
This investigation aims to investigate the impact of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3B (APOBEC3B/A3B) on the malignant biological characteristics of bladder cancer. Additionally, the study examines the potential mechanisms of APOBEC3B's action to assess its feasibility as a therapeutic strategy for bladder cancer.
The investigation first confirmed APOBEC3B expression in bladder cancer using bioinformatics and experimental validation. Then, the relationship between APOBEC3B expression and various parameters was analyzed, with gene set enrichment analysis (GSEA) to explore pathways. The IMvigor210 cohort was analyzed to validate the correlation between APOBEC3B expression and immunotherapy efficacy.
Cellular and animal experiments further validated the impact of APOBEC3B on bladder cancer biology. High APOBEC3B expression in bladder cancer patients is associated with an increased frequency of somatic mutations. APOBEC3B expression levels are significantly correlated with the infiltration of various immune cells and the expression of immune checkpoint-related genes. Moreover, high APOBEC3B expression is associated with increased tumor mutation burden. In the IMvigor210 cohort, APOBEC3B expression is significantly upregulated in individuals with positive responses to immunotherapy. Our study suggests that APOBEC3B plays a key role in promoting the initiation and progression of bladder cancer. Additionally, bladder cancer cells with overexpressed APOBEC3B can enhance the polarization of M2-like tumor-associated macrophages.
The research demonstrates that APOBEC3B exhibits high expression levels in bladder cancer and can enhance its malignant biological behavior. APOBEC3B may serve as a promising therapeutic target in future treatments.
本研究旨在探讨载脂蛋白B信使核糖核酸编辑酶催化多肽3B（APOBEC3B/A3B）对膀胱癌恶性生物学特性的影响。此外，该研究还考察了APOBEC3B作用的潜在机制，以评估其作为膀胱癌治疗策略的可行性。
该研究首先通过生物信息学和实验验证确认了APOBEC3B在膀胱癌中的表达。然后，分析了APOBEC3B表达与各种参数之间的关系，并采用基因集富集分析（GSEA）来探索相关通路。对IMvigor210队列进行分析，以验证APOBEC3B表达与免疫治疗疗效之间的相关性。
细胞和动物实验进一步验证了APOBEC3B对膀胱癌生物学的影响。膀胱癌患者中APOBEC3B高表达与体细胞突变频率增加有关。APOBEC3B表达水平与各种免疫细胞的浸润以及免疫检查点相关基因的表达显著相关。此外，APOBEC3B高表达与肿瘤突变负担增加有关。在IMvigor210队列中，对免疫治疗有阳性反应的个体中APOBEC3B表达显著上调。我们的研究表明，APOBEC3B在促进膀胱癌的发生和发展中起关键作用。此外，APOBEC3B过表达的膀胱癌细胞可增强M2样肿瘤相关巨噬细胞的极化。
该研究表明，APOBEC3B在膀胱癌中呈现高表达水平，并可增强其恶性生物学行为。APOBEC3B可能成为未来治疗中有前景的治疗靶点。
